Analyst Ratings for Pacira BioSciences
Portfolio Pulse from Benzinga Insights
In the last quarter, Pacira BioSciences (NASDAQ:PCRX) received 3 bullish and 1 somewhat bullish ratings from analysts. The average 12-month price target for the company is $67.75, a 7.19% decrease from the previous average of $73.00.
July 13, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pacira BioSciences received positive analyst ratings, but the average 12-month price target has decreased, indicating a potential short-term downward pressure on the stock.
Analyst ratings are a significant factor influencing stock prices. While Pacira BioSciences received mostly bullish ratings, the decrease in the average 12-month price target could indicate less optimism about the company's future performance, potentially leading to a short-term decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100